Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

83.84 +2.47 (+3.04%)
Streaming Delayed Price Updated: 2:33 PM EDT, Jul 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
87 88 Next >
Nvidia's $4 Trillion Milestone Lifts Wall Street: What's Moving Markets Wednesday?
Wall Street rose on Wednesday as investors shrugged off fresh trade uncertainty after the White House delayed the start of new tariffs to Aug. 1, raising hopes for new rounds of negotiations. 
Via Benzinga
Topics World Trade
P/E Ratio Insights for Merck & Co
Via Benzinga
Explore the top gainers and losers within the S&P500 index in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda's looming patent loss. 
Via Benzinga
Topics Intellectual Property
Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma
The takeover target just launched its first drug last summer. Shares have mostly trended higher since. 
Via Investor's Business Daily
Topics Government
Merck To Acquire Verona For $10B In Bid To Expand Cardio-Pulmonary Pipeline
Merck will acquire Verona for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion. 
Via Stocktwits
Topics Government
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Merck (NYSE:MRK)
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Merck (NYSE:MRK) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Stocks
Trump's 'Big, Beautiful Bill' Hands $5 Billion Win To Big Pharma: Report
Trump's $3.3 trillion domestic agenda bill, passed by the House on Thursday, includes a significant victory for pharmaceutical companies . 
Via Benzinga
Topics Government
2 S&P 500 Stocks with Promising Prospects and 1 to Question
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth,... 
Via StockStory
Topics Stocks
Uncover the latest developments among S&P500 stocks in today's session.
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday. 
Via Chartmill
AstraZeneca In $15B Talks For Drug That Could Upend Lung Cancer Treatment
Via Benzinga
What's going on in today's session: S&P500 gap up and gap down stocks
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Thursday to find the gap up and gap down stocks in today's session. 
Via Chartmill
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Merck's Hypertension Drug On FDA Fast Track For Label Expansion
Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact. 
Via Benzinga
MERCK & CO. INC. (NYSE:MRK) – A Strong Value Candidate in Healthcare
MERCK & CO. (NYSE:MRK) is an undervalued pharmaceutical stock with strong profitability, a healthy balance sheet, and a reliable dividend, making it a candidate for value investors. 
Via Chartmill
Dogs Of The Dow: How You Can Get Dividend Stocks With Yields Up To 6.3%
The Dow Jones Industrial Average stocks average a 2% dividend yield through the first six months of 2025. Here are the top yields. 
Via Benzinga
Topics Stocks
Dow Jones 2025 First Half Scoreboard: Top 10 Winners, Losers — Where Do Nvidia, Apple Stock Rank?
The Dow Jones Industrial Average was up around 4% in the first half of 2025 with a large majority of the 30 stocks positive. 
Via Benzinga
Topics Stocks
HDV Is a Popular Dividend ETF for Passive Income. But Is It the Best?
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide. 
Via Investor's Business Daily
Peering Into Merck & Co's Recent Short Interest
Via Benzinga
1 Profitable Stock to Consider Right Now and 2 to Think Twice About
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
3 Absurdly Cheap Stocks Ready for a Breakout
All three stocks are poised to go higher. 
Via The Motley Fool
RFK Jr's CDC Panel Recommends Merck's RSV Shot For Infants
CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in clinical trials. 
Via Benzinga
CDC Vaccine Panel Overhauled by RFK Jr. Votes To Drop Mercury Preservative, Critics Sound Alarm
The panel also voted to recommend Merck’s RSV antibody drug Enflonsia for newborns whose mothers didn’t receive prenatal protection. 
Via Stocktwits
5 Biotech Stocks with Highly Anticipated Pending Results
Via Stocktwits
Topics Intellectual Property
Elanco Animal Health Gets Its Bite Back, Pipeline Efforts Earn Praise
Elanco upgraded to Outperform by William Blair as pipeline gains traction and EMA backs Zenrelia ahead of expected Q3 approval. 
Via Benzinga
2 Stocks Too Cheap to Ignore at These Prices
Via The Motley Fool
Topics Artificial Intelligence Lawsuit
RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group
Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts. 
Via Benzinga
Merck's Hypertension Drug Cuts Clinical Worsening Risk In Over 70% Of Patients On Double Background Therapy
Merck's Winrevair reduced clinical worsening in PAH patients in the Phase 3 HYPERION trial, building on prior positive study outcomes. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
87 88 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.